Medical Xpress reports the figure came at the top dose in a trial running about 80 weeks, a key group for Lilly's triple agonist.
Recap by typeshit. Post by Medical Xpress on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research shown at the EADV Congress 2026 found 39% of users reported nails lifting versus 9% of non-users, plus more hair loss. It's self-reported and shows no causation.
3:15
CBS News reports two deaths tied to an unregulated weight-loss drug sold outside approved channels. The full investigation has the details.
Loading…